Hypertriglyceridemia clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 21-75
This study is designed to assess the efficacy, safety, and tolerability of different doses and dose regimens (QW or every 2 weeks [Q2W]), subcutaneous (SC) dosing of BIO89-100 compared to placebo in subjects with Severe Hypertriglyceridemia (SHTG).
San Francisco, California and other locations